ArticlePhysics and imaging in radiation oncology2026
A component-wise commissioning and validation framework for non-transit electronic portal imaging device patient-specific quality assurance.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: The American Association of Physicists in Medicine Task Group 307 (AAPM TG-307) recommends validation of electronic portal imaging device (EPID) patient-specific quality assurance (PSQA), including verification of measured and calculated components. This study established a TG-307-aligned commissioning and benchmarking framework for non-transit EPID pre-treatment PSQA. Material and methods: Fraction Zero Absolute Dose (FZAD) was commissioned on two TrueBeam linear accelerators equipped with amorphous silicon (aS) aS1000 and aS1200 EPIDs across flattened and flattening filter-free (FFF) photon beams (6MV/10MV) and two multi-leaf-collimator models. EPID performance was characterised for dose-rate linearity. Independent validation of measured and predicted dose components was performed using ion chamber, phantom-based, and treatment planning system dose planes in geometry replicating EPID configuration. System performance was benchmarked against Portal Dosimetry (PDIP) and phantom-based PSQA across >800 clinical fields. Error-detection sensitivity was evaluated using receiver operating characteristic (ROC) analysis of externally supplied audit plans. Results: The aS1200 panel was linear across dose-rate and source-to-imager distance (SID) conditions, whereas the aS1000 exhibited saturation for FFF beams at shorter SIDs, with up to 5% under-response, with linearity restored at ≥150 cm SID. Independent component validation achieved mean gamma pass rates ≥97% (3%/2 mm). Bland-Altman analysis showed concordance within 95% limits of agreement, supporting equivalence in clinical decision-making. Sensitivity testing demonstrated discrimination at 2%/2 mm (area under ROC curve of 0.886), with improved detection compared to phantom-based PSQA at high specificity. Conclusions: A TG-307-aligned framework enables component-level interpretability and actionable insight for tolerance definition and model optimisation of EPID PSQA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.